← All stocks

Dianthus Therapeutics, Inc. /DE/

DNTH Scheduled selling only
CIK 0001690585 #1220 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$2.79M
$0.00 on a plan · $2.79M straight out of an exercise
Sold at will
$0.00
0 of 4 sales
Net
−$2.79M
$0.00 against sales at will

By person

9 insiders · 4 transactions
11.0×

Marino Garcia holds 11.0 times base salary in stock. $6.97M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Marino Garcia last reported holding, valued at $106.74, the price Common Stock was last bought or sold at on the open market here, on 1 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Randhawa Simrat
EVP, Head of R&D
$2.46M (3) scheduled
−$2.46M
4,000
0.0072%
$426.96K
0.0%
Read Simon
Director
$326.55K (1) scheduled
−$326.55K
0
0.0000%
$0.00
Garcia Marino
CEO AND PRESIDENT
65,292
0.1167%
$6.97M
Veness Adam M
SVP, General Counsel and Sec.
15,000
0.0268%
$1.60M
Fairmount Funds Management LLC entity
Director
0
0.0000%
$0.00
−100.0%
McGeorge Anne
Director
0
0.0000%
$0.00
Savitz Ryan
EVP, CFO & CBO
0
0.0000%
$0.00
Soteropoulos Paula
Director
0
0.0000%
$0.00
CARR EDWARD
CHIEF ACCOUNTING OFFICER
0
0.0000%
$0.00
Insider
Date
Role
Action
Shares
Price
Amount
Randhawa Simrat
1 Sep 2026
EVP, Head of R&D
Sold after exercise
13,309
$106.74
$1.42M
Randhawa Simrat
1 Sep 2026
EVP, Head of R&D
Sold after exercise
7,215
$106.25
$766.59K
Randhawa Simrat
1 Sep 2026
EVP, Head of R&D
Sold after exercise
2,600
$105.19
$273.49K
Read Simon
19 Aug 2026
Director
Sold after exercise
2,778
$117.55
$326.55K

What was left out

Form 4 filings counted 2
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 4
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 25,902
History held since 27 Jun 2018